Pre-exposure prevention trial reduced risk of symptomatic Covid-19, with no severe disease or Covid-19-related deaths in the Evusheld group
Support for biologics manufacturability and Industry 4.0 initiatives
Bionova Scientific’s process development capabilities are particularly highly regarded in the industry, and it has a rich track record regarding complex next-generation antibody drugs, which are typically challenging to manufacture
This marks an expansion of the companies' existing collaboration and further validates the use of Albumedix Recombumin rHA products in the manufacturing process and final formulation of critical vaccines
Marks the second of three biosimilars Amneal expects to receive U.S. approval for in 2022
Support for bioprocess, cell and gene therapy, and industry 4.0 initiatives
New high-throughput, no-wash assays contribute to the development, manufacture and quality control of safer, more effective biotherapeutics
R&D investment up 11.7% to 4.1 billion EUR in 2021 (20.0% of net sales)
Ondexxya is the first approved reversal agent specifically for Factor Xa inhibitors, providing a major advance in the treatment of patients hospitalised with life-threatening bleeding
Evusheld significantly reduced the risk of developing symptomatic COVID-19 in PROVENT Phase III trial, with protection lasting at least six months
Subscribe To Our Newsletter & Stay Updated
